Allogene Therapeutics (ALLO) Payables (2019 - 2025)
Historic Payables for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $3.7 million.
- Allogene Therapeutics' Payables fell 3281.87% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 3281.87%. This contributed to the annual value of $5.4 million for FY2024, which is 852.98% down from last year.
- Per Allogene Therapeutics' latest filing, its Payables stood at $3.7 million for Q3 2025, which was down 3281.87% from $4.9 million recorded in Q2 2025.
- In the past 5 years, Allogene Therapeutics' Payables registered a high of $14.9 million during Q1 2021, and its lowest value of $3.7 million during Q3 2025.
- For the 5-year period, Allogene Therapeutics' Payables averaged around $9.0 million, with its median value being $9.7 million (2022).
- Per our database at Business Quant, Allogene Therapeutics' Payables soared by 10662.59% in 2021 and then tumbled by 6250.0% in 2025.
- Quarter analysis of 5 years shows Allogene Therapeutics' Payables stood at $10.3 million in 2021, then skyrocketed by 35.45% to $13.9 million in 2022, then tumbled by 57.54% to $5.9 million in 2023, then fell by 8.53% to $5.4 million in 2024, then tumbled by 31.42% to $3.7 million in 2025.
- Its last three reported values are $3.7 million in Q3 2025, $4.9 million for Q2 2025, and $5.1 million during Q1 2025.